Price
Financials
Consolidated, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 85.83 | 96.29 | 117.86 | 81.82 | 92.14 | 96.33 | 108.73 | 71.76 | 88.71 | 108.66 | 105.27 | 94.18 |
| Expenses | 76.50 | 84.75 | 102.21 | 73.78 | 82.61 | 84.77 | 94.13 | 67.51 | 82.95 | 95.85 | 98.08 | 91.73 |
| Operating Profit | 9.33 | 11.54 | 15.65 | 8.04 | 9.53 | 11.56 | 14.60 | 4.25 | 5.76 | 12.81 | 7.19 | 2.45 |
| OPM % | 10.87% | 11.98% | 13.28% | 9.83% | 10.34% | 12.00% | 13.43% | 5.92% | 6.49% | 11.79% | 6.83% | 2.60% |
| Other Income | 1.42 | 1.11 | 1.53 | 1.00 | 1.32 | 1.75 | 1.71 | 1.48 | 2.04 | 1.70 | 6.16 | 0.99 |
| Interest | 1.22 | 1.70 | 2.28 | 2.86 | 2.89 | 2.73 | 2.91 | 3.30 | 3.16 | 3.43 | 3.31 | 3.64 |
| Depreciation | 4.09 | 3.94 | 3.91 | 4.94 | 5.00 | 4.88 | 5.29 | 4.86 | 4.98 | 5.03 | 5.10 | 5.37 |
| Profit before tax | 5.44 | 7.01 | 10.99 | 1.24 | 2.96 | 5.70 | 8.11 | -2.43 | -0.34 | 6.05 | 4.94 | -5.57 |
| Tax % | 23.71% | 31.81% | 26.48% | 27.42% | 19.59% | 30.00% | 39.70% | -22.63% | 23.53% | 27.27% | 24.29% | -28.01% |
| Net Profit | 4.15 | 4.78 | 8.09 | 0.90 | 2.38 | 4.00 | 4.88 | -1.87 | -0.42 | 4.40 | 3.74 | -4.02 |
| EPS in Rs | 0.85 | 0.98 | 1.66 | 0.18 | 0.49 | 0.82 | 1.00 | -0.38 | -0.09 | 0.90 | 0.70 | -0.75 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 269 | 235 | 273 | 335 | 278 | 307 | 333 | 399 | 367 | 379 | 374 | 397 |
| Expenses | 239 | 203 | 238 | 293 | 255 | 268 | 292 | 347 | 326 | 335 | 344 | 369 |
| Operating Profit | 30 | 32 | 35 | 42 | 23 | 40 | 41 | 52 | 41 | 44 | 30 | 28 |
| OPM % | 11% | 13% | 13% | 13% | 8% | 13% | 12% | 13% | 11% | 12% | 8% | 7% |
| Other Income | -2 | 5 | 9 | 2 | 5 | -3 | 4 | 6 | 5 | 6 | 11 | 11 |
| Interest | 14 | 10 | 9 | 11 | 13 | 11 | 8 | 6 | 7 | 11 | 13 | 14 |
| Depreciation | 9 | 9 | 10 | 11 | 14 | 16 | 16 | 17 | 16 | 20 | 20 | 20 |
| Profit before tax | 5 | 18 | 25 | 22 | 0 | 10 | 21 | 35 | 24 | 18 | 8 | 5 |
| Tax % | 5% | -6% | 23% | 30% | -4,600% | 28% | 31% | 31% | 27% | 32% | 29% | |
| Net Profit | 5 | 19 | 19 | 15 | 3 | 7 | 15 | 24 | 17 | 12 | 6 | 4 |
| EPS in Rs | 3.17 | 0.68 | 1.50 | 2.99 | 5.01 | 3.54 | 2.50 | 1.09 | 0.76 | |||
| Dividend Payout % | 16% | 4% | 4% | 5% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | 3% | 4% | -2% | 8% | ||
| Compounded Profit Growth | -7% | -17% | -44% | -61% | ||
| Stock Price CAGR | % | 24% | 4% | 89% | ||
| Return on Equity | 8% | 7% | 5% | 2% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 16 | 16 | 16 | 16 | 49 | 49 | 49 | 54 |
| Reserves | 86 | 91 | 110 | 129 | 135 | 138 | 145 | 159 | 152 | 190 | 204 | 243 |
| Borrowings | 93 | 96 | 81 | 81 | 77 | 90 | 82 | 53 | 62 | 112 | 118 | 127 |
| Other Liabilities | 78 | 61 | 60 | 81 | 100 | 82 | 82 | 112 | 79 | 96 | 102 | 116 |
| Total Liabilities | 265 | 256 | 259 | 298 | 328 | 325 | 325 | 342 | 342 | 447 | 472 | 539 |
| Fixed Assets | 87 | 92 | 89 | 94 | 106 | 116 | 107 | 106 | 109 | 161 | 164 | 162 |
| CWIP | 6 | 3 | 4 | 8 | 13 | 10 | 11 | 12 | 27 | 42 | 70 | 96 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 172 | 161 | 166 | 196 | 209 | 200 | 208 | 224 | 206 | 244 | 237 | 282 |
| Total Assets | 265 | 256 | 259 | 298 | 328 | 325 | 325 | 342 | 342 | 447 | 472 | 539 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 22 | 32 | 37 | 35 | 22 | 32 | 49 | 38 | 16 | 41 | 50 | |
| Cash from Investing Activity | -12 | -7 | -26 | -21 | -19 | -6 | -14 | -35 | -73 | -40 | -55 | |
| Cash from Financing Activity | -10 | -25 | -10 | -15 | -2 | -26 | -33 | 1 | 60 | -9 | 28 | |
| Net Cash Flow | -0 | -0 | 1 | -1 | 1 | -0 | 2 | 3 | 3 | -8 | 23 | |
| Free Cash Flow | 9 | 24 | 8 | 15 | 3 | 25 | 34 | 1 | -57 | 1 | 11 | |
| CFO/OP | 77% | 109% | 117% | 85% | 119% | 83% | 121% | 86% | 46% | 92% | 177% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 111 | 120 | 137 | 119 | 101 | 89 | 86 | 98 | 87 | 100 | 103 | 106 |
| Inventory Days | 93 | 87 | 108 | 134 | 126 | 144 | 125 | 171 | 99 | 173 | 188 | 207 |
| Days Payable | 129 | 109 | 137 | 172 | 165 | 168 | 149 | 185 | 107 | 133 | 151 | 161 |
| Cash Conversion Cycle | 75 | 99 | 108 | 81 | 63 | 65 | 62 | 85 | 79 | 140 | 140 | 152 |
| Working Capital Days | 38 | 34 | 54 | 37 | 39 | 46 | 49 | 67 | 67 | 57 | 60 | 41 |
| ROCE % | 13% | 14% | 14% | 15% | 5% | 11% | 12% | 17% | 10% | 8% | 5% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 33.26% | 33.26% | 33.26% | 33.26% | 33.26% | 33.26% | 33.26% | 33.26% | 33.26% | 33.26% | 30.35% | 30.36% |
| FIIs | 0.00% | 0.00% | 0.01% | 0.00% | 0.00% | 0.21% | 0.01% | 0.03% | 0.00% | 0.02% | 0.00% | 0.03% |
| DIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.24% | 0.24% | 0.24% | 0.24% | 0.20% | 0.07% | 1.34% |
| Public | 66.75% | 66.74% | 66.74% | 66.74% | 66.73% | 66.29% | 66.49% | 66.46% | 66.52% | 66.52% | 69.57% | 68.28% |
| No. of Shareholders | 15,305 | 17,342 | 17,100 | 17,483 | 17,716 | 17,450 | 17,448 | 16,641 | 17,282 | 17,251 | 16,636 | 14,510 |
Fundamentals
Market Cap₹ 729 Cr.
Current Price₹ 135
Stock P/E197
Book Value₹ 55.4
ROCE4.76 %
ROE1.59 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)8%
Compounded Profit Growth (TTM)-61%
Consolidated figures.
Valuation
Market capRs 733 Cr
Enterprise valueRs 816 Cr
P/E (TTM)198.12x
Price to book2.48x
Price to sales1.85x
EV / EBITDA20.88x
EV / EBIT43.84x
EV / sales2.06x
Price to cash flow14.80x
Earnings yield0.50%
P/E, 3-year average38.09x
P/B, 3-year average1.53x
P/E, 5-year average26.93x
P/B, 5-year average1.37x
Profitability
Operating margin (excl. other income)8.02%
Operating margin (incl. other income)11.05%
EBITDA margin9.85%
Pre-tax margin1.28%
Net profit margin0.93%
Net margin, latest quarter-4.27%
ROE2.13%
ROCE5.40%
ROA1.16%
ROE, 3-year average4.98%
ROCE, 3-year average7.84%
ROA, 3-year average2.73%
ROE, 5-year average7.32%
ROCE, 5-year average10.52%
ROA, 5-year average3.94%
ROIC (approx.)3.49%
Tax rate28.87%
Other income / net worth3.84%
Growth
Sales growth (latest year)-1.22%
Profit growth (latest year)-52.01%
Sales CAGR, 3 years-2.06%
Sales CAGR, 5 years4.03%
Profit CAGR, 3 years-37.94%
Profit CAGR, 5 years-4.42%
Sales growth QoQ-10.53%
Profit growth QoQ-207.49%
Sales growth YoY (latest quarter)31.24%
Per share
EPS (TTM)Rs 0.69
EPS (latest year)Rs 1.09
EPS (latest quarter)Rs -0.75
EPS, 3-year averageRs 2.38
EPS, 5-year averageRs 4.22
Book value per shareRs 55.35
Sales per shareRs 74.17
Cash flow per shareRs 9.26
Free cash flow per shareRs 2.06
Efficiency
Asset turnover0.69x
Fixed asset turnover2.31x
Inventory turnover2.37x
Inventory days154 days
Debtor days106 days
Debtors turnover3.43x
Creditor days161 days
Cash conversion cycle152 days
Working capital days41 days
Leverage
Total debtRs 127 Cr
Cash and bankRs 43 Cr
Net debtRs 83 Cr
Debt to equity0.43x
Net debt / EBITDA2.13x
Interest coverage1.38x
Current ratio (filing 2026-03-31)1.45x
Quick ratio (filing 2026-03-31)0.96x
Trade payables (filing 2026-03-31)Rs 73 Cr
Owners' fund to total sources54.95%
Debt to assets23.48%
Cash flow
Cash from Operating Activity (latest year)Rs 50 Cr
Cash from Investing Activity (latest year)Rs -55 Cr
Cash from Financing Activity (latest year)Rs 28 Cr
Net Cash Flow (latest year)Rs 23 Cr
Free cash flow (latest year)Rs 11 Cr
FCFE (approx.: FCF + change in debt)Rs 20 Cr
Cash from ops / profit, 5 years2.62x
Sales to cash flow7.56x
Statement figures
Net sales (TTM)Rs 397 Cr
Net sales (latest year)Rs 374 Cr
Sales (latest quarter)Rs 94 Cr
Operating profit excl. other income (latest year)Rs 30 Cr
Operating profit (latest quarter)Rs 2 Cr
Other income (TTM)Rs 11 Cr
EBITDA (TTM)Rs 39 Cr
PBDT (TTM)Rs 26 Cr
Profit before tax (TTM)Rs 5 Cr
Tax (latest year)Rs 2 Cr
Net profit (TTM)Rs 4 Cr
Net profit (latest year)Rs 6 Cr
Net profit (latest quarter)Rs -4 Cr
Depreciation (TTM)Rs 20 Cr
Depreciation (latest quarter)Rs 5 Cr
Interest (TTM)Rs 14 Cr
Cost of goods sold (latest year)Rs 222 Cr
Total expenditure (latest year)Rs 344 Cr
Total income (latest year)Rs 386 Cr
Share capitalRs 54 Cr
ReservesRs 243 Cr
Shareholders' fundsRs 296 Cr
Total assetsRs 539 Cr
Net blockRs 162 Cr
Capital work in progressRs 96 Cr
InvestmentsRs 0 Cr
ReceivablesRs 109 Cr
InventoryRs 94 Cr
Other liabilitiesRs 116 Cr
Shares outstanding (crore)5.35
Ownership
Promoter holding30.36% (-2.90 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 198.1 is at the 98th percentile of its own 8.4-year range
(median 31.6, low 0.0, high 199.5).
P/B 2.48 is at the 76th percentile (median 1.86).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | ZIMLAB | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -0.6% | -2.8% | +2.2 pts |
| 1 month | +16.2% | -6.8% | +23.0 pts |
| 3 months | +12.3% | -7.6% | +19.9 pts |
| 6 months | +127.4% | +0.4% | +127.0 pts |
| 1 year | +85.9% | -9.9% | +95.8 pts |
| 2 years | +24.9% | -13.6% | +38.5 pts |
| 3 years | +13.7% | +14.2% | -0.5 pts |
| 5 years | +199.3% | +27.9% | +171.4 pts |
1 mutual fund schemes hold about ₹8 Cr.
Over three months 0 bought more and 0 sold (share counts, price move removed).
| Fund | Weight | Est. Cr | 3m shares |
|---|---|---|---|
| Tata India Pharma & Healthcare Fund | 0.49% | 8 |
Red flags
F-score 4 of 8| look | Profit leans on other income Other income was 139% of pre-tax profit in 2026 |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹94 Cr +31.2% vs Jun 2025.
Net loss ₹4 Cr.
Against our estimate for Jun 2026: sales +25.2%, profit -447.2% big miss. Our estimate for Sep 2026: sales Rs 101 Cr, profit Rs 2 Cr (how).
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
| Ex-date | Action | Factor |
|---|---|---|
| 2024-06-20 | Annual General Meeting | |
| 2023-07-03 | Annual General Meeting | |
| 2022-12-22 | Bonus 2:1 | 0.3333 |
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Close to Close price movement greater than 75perc in previous 6 monthsHigh low price variation greater than 100perc in previous 6 monthsScrip PE is greater than 50 (4 trailing quarters)
Quick answers
What is the market cap of Zim Laboratories Ltd?
Zim Laboratories Ltd (ZIMLAB) has a market capitalisation of Rs 729 Cr. at the 2026-10-01 close.
What is the P/E ratio of Zim Laboratories Ltd?
Zim Laboratories Ltd trades at a P/E of 197 on trailing twelve-month profit, at the 2026-10-01 close.
What were Zim Laboratories Ltd's latest quarterly results?
In the Jun 2026 quarter, Zim Laboratories Ltd sales was Rs 94 Cr (+31.2% vs Jun 2025) with a net loss of Rs 4 Cr.
What is the 52-week high and low of Zim Laboratories Ltd?
The 52-week high is Rs 144.49 and the 52-week low is Rs 59.31.